Apogem Capital’s Cellectis CLLS Stock Holding History

Apogem Capital’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,664	Closed	-$216K	–	198
2021 Q1	$216K	Buy	+10,664	New	+$264K	0.15%	152

Other funds holding CLLS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Apogem Capital's CLLS Position: Q2 2021 in Review

Apogem Capital sold out of Cellectis (CLLS) in Q2 2021, closing a stake of 10,664 shares — an estimated $216K sold.

Apogem Capital first reported a position in CLLS in Q1 2021 and held it in 1 quarter. The position peaked at $216K in Q1 2021. 78 funds tracked by Wall St. Rank hold CLLS as of Q2 2021.

Apogem Capital reported no remaining Cellectis position as of Q2 2021 after selling out during the quarter.
Apogem Capital sold 10,664 Cellectis shares in Q2 2021, an estimated $216K.
Apogem Capital first reported a position in Cellectis in Q1 2021 and held it in 1 quarter.
Apogem Capital's Cellectis position peaked at $216K in Q1 2021.
78 funds tracked by Wall St. Rank held Cellectis as of Q2 2021.

Based on Apogem Capital's 13F filing for Q2 2021, filed 16 Aug 2021.